Revvity's (NYSE:RVTY) Q4 CY2025 Sales Beat Estimates

Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance of $2.98 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $1.70 per share was 7.8% above analysts’ consensus estimates.

Is now the time to buy Revvity? Find out by accessing our full research report, it’s free.

"We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations," said Prahlad Singh, president and chief executive officer of Revvity.

Company Overview

Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Revvity struggled to consistently generate demand over the last five years as its sales dropped at a 5.5% annual rate. This was below our standards and suggests it’s a low quality business.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Revvity’s annualized revenue growth of 1.9% over the last two years is above its five-year trend, but we were still disappointed by the results.

Revvity also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Revvity’s organic revenue averaged 2% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.

This quarter, Revvity reported year-on-year revenue growth of 5.8%, and its $772.1 million of revenue exceeded Wall Street’s estimates by 1.1%.

Looking ahead, sell-side analysts expect revenue to grow 2.8% over the next 12 months, similar to its two-year rate. This projection doesn't excite us and indicates its newer products and services will not accelerate its top-line performance yet.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our free report one of our favorites growth stories.

Operating Margin

Revvity has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 18.4%.

Analyzing the trend in its profitability, Revvity’s operating margin decreased by 13.8 percentage points over the last five years, but it rose by 1.6 percentage points on a two-year basis. Still, shareholders will want to see Revvity become more profitable in the future.

In Q4, Revvity generated an operating margin profit margin of 14.5%, down 1.8 percentage points year on year. This reduction is quite minuscule and indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for Revvity, its EPS declined by 9.4% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

Diving into the nuances of Revvity’s earnings can give us a better understanding of its performance. As we mentioned earlier, Revvity’s operating margin declined by 13.8 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q4, Revvity reported adjusted EPS of $1.70, up from $1.42 in the same quarter last year. This print beat analysts’ estimates by 7.8%. Over the next 12 months, Wall Street expects Revvity’s full-year EPS of $5.07 to grow 4.8%.

Key Takeaways from Revvity’s Q4 Results

It was good to see Revvity provide full-year revenue guidance that slightly beat analysts’ expectations. We were also happy its organic revenue narrowly outperformed Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $109.50 immediately after reporting.

Revvity had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).